Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
25.58
+0.58 (2.32%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC.
The company was incorporated in 2020 and is based in Palo Alto, California.
Evommune, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | Nov 6, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 48 |
| CEO | Luis Pena |
Contact Details
Address: 1841 Page Mill Road, Suite 100 Palo Alto, California 94304 United States | |
| Phone | (925) 247-4481 |
| Website | evommune.com |
Stock Details
| Ticker Symbol | EVMN |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0002044725 |
| CUSIP Number | 30054Y107 |
| ISIN Number | US30054Y1073 |
| Employer ID | 85-0742575 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Luis C. Pena | Founder, President, Chief Executive Officer and Director |
| Kyle Carver CPA, M.B.A. | Chief Financial Officer |
| Gregory S. Moss Esq. | Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer |
| Dr. Eugene Andrew Bauer M.D. | Co-Founder, Chief Medical Officer and Director |
| Dr. Jeegar Patel Ph.D. | Chief Scientific Officer |
| Janice Drew M.P.H. | Chief of Development Operations |
| Dr. Lou Sehl Ph.D. | Senior Vice President of Technical Operations |
| Dr. Daniel J. Burge M.d. | Senior Vice President of Clinical Development |
| J. Mark Jackson M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | EFFECT | Notice of Effectiveness |
| Apr 24, 2026 | 424B3 | Prospectus |
| Apr 21, 2026 | ARS | Filing |
| Apr 21, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 13, 2026 | 8-K | Current Report |
| Mar 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |